DNA Replication Licensing Protein MCM10 Promotes Tumor Progression and Is a Novel Prognostic Biomarker and Potential Therapeutic Target in Breast Cancer
- Supplementary File 1:
PDF-Document (PDF, 979 KiB)
Mahadevappa, R.; Neves, H.; Yuen, S.M.; Jameel, M.; Bai, Y.; Yuen, H.-F.; Zhang, S.-D.; Zhu, Y.; Lin, Y.; Kwok, H.F. DNA Replication Licensing Protein MCM10 Promotes Tumor Progression and Is a Novel Prognostic Biomarker and Potential Therapeutic Target in Breast Cancer. Cancers 2018, 10, 282. https://doi.org/10.3390/cancers10090282
Mahadevappa R, Neves H, Yuen SM, Jameel M, Bai Y, Yuen H-F, Zhang S-D, Zhu Y, Lin Y, Kwok HF. DNA Replication Licensing Protein MCM10 Promotes Tumor Progression and Is a Novel Prognostic Biomarker and Potential Therapeutic Target in Breast Cancer. Cancers. 2018; 10(9):282. https://doi.org/10.3390/cancers10090282
Chicago/Turabian StyleMahadevappa, Ravikiran, Henrique Neves, Shun M. Yuen, Muhammad Jameel, Yuchen Bai, Hiu-Fung Yuen, Shu-Dong Zhang, Youzhi Zhu, Yao Lin, and Hang F. Kwok. 2018. "DNA Replication Licensing Protein MCM10 Promotes Tumor Progression and Is a Novel Prognostic Biomarker and Potential Therapeutic Target in Breast Cancer" Cancers 10, no. 9: 282. https://doi.org/10.3390/cancers10090282


